Jacobio Pharma (HKG: 1167), a leading biopharmaceutical company based in China, has announced that its New Drug Application (NDA) for glecirasib has been accepted by China’s National Medical Products Administration (NMPA) with priority review status. The KRAS G12C inhibitor is being reviewed for its potential as a treatment for second-line and above advanced or metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation.
Glecirasib, an in-house developed drug by Jacobio, is currently the subject of numerous studies across China, the US, and Europe for its efficacy in treating NSCLC, colorectal cancer, and pancreatic cancer. Recognizing its promising results in terms of efficacy and safety, the drug was awarded breakthrough therapy designation (BTD) status in China in December 2022 specifically for the NSCLC indication.- Flcube.com
